Michelle Mitchell – CEO, Multiple Sclerosis Society, UK
Michelle Mitchell, CEO of the Multiple Sclerosis Society in the UK since 2013, discusses her charity’s aims; their focus on research and development; funding in the face of Brexit; and…
Address: Building 4, Chiswick Park, 566 Chiswick High Road, London, W4 5YEUK,United Kingdom
Tel: + 44 208 742 5250
Ranbaxy Laboratories Limited (Ranbaxy), India’s largest pharmaceutical company, is an integrated, research based, international pharmaceutical company, producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy today has a presence in 23 of the top 25 pharmaceutical markets of the world. The Company has a global footprint in 46 countries, world-class manufacturing facilities in 7 countries and serves customers in over 125 countries.
In June 2008, Ranbaxy entered into an alliance with one of the largest Japanese innovator companies, Daiichi Sankyo Company Ltd., to create an innovator and generic pharmaceutical powerhouse. The combined entity now ranks among the top 20 pharmaceutical companies, globally. The transformational deal will place Ranbaxy in a higher growth trajectory and it will emerge stronger in terms of its global reach and in its capabilities in drug development and manufacturing.
Ranbaxy (U.K.) Ltd. (RUKL) is a wholly owned subsidiary of Ranbaxy Laboratories Ltd. and it plays a significant role in Ranbaxy’s European presence.
RUKL has made considerable progress in enhancing its product portfolio and for securing the product basket by in-licensing products. Deals have been signed with various companies, for a number of different molecules in different therapeutic areas. These are over and above the in-house product pipeline and give further impetus to RUKL’s growth in the UK pharmaceuticals market.
Top 10 Products (2009)
• Valacyclovir
• Simvastatin
• Co-Amoxyclav
• Ciprofloxacin and Combinations
• Amoxycillin and Combinations
• Isotretinoin
• Ketorolac Tromethamine
• Loratadine and Combinations
• Ginseng+Vitamins
• Cephalexin
• Atorvastatin and Combinations
Michelle Mitchell, CEO of the Multiple Sclerosis Society in the UK since 2013, discusses her charity’s aims; their focus on research and development; funding in the face of Brexit; and…
Recipient of the 2018 Brain Prize for research for groundbreaking research on the generic and molecular basis of Alzheimer’s Disease, the UCL’s Professor John Hardy discusses recent progress in dementia…
Tim de Gavre, country head of Sandoz UK, discusses the role of biosimilars in driving innovation, the threats and opportunities of Brexit to the biosimilars industry, and how Sandoz partners…
Mike Belton of the British Swiss Chamber of Commerce discusses the capabilities of the organization, its role within the British and Swiss investment ecosystem, and how Switzerland can act as…
John Smith, chief executive of the PAGB, the UK’s consumer healthcare industry association, discusses the potential impacts of Brexit on the PAGB’s members, the importance of consumer healthcare to the…
Sarah Haywood, CEO of MedCity, the life science cluster for London, Oxford and Cambridge in the southeast of England, discusses the organization’s strategy, key achievements, Brexit, and supporting SMEs. Why…
In an exclusive interview at the BioPharma Ambition Conference 2016 in Dublin, Sir Andrew Dillon, founding CEO of the UK National Institute for Health and Care Excellence (NICE), shares his…
Lord Philip Hunt, a former UK health minister during the Blair and Brown governments, shares his thoughts on procurement in healthcare, structural change and its impact, and how funds may…
British consultant, speaker and author, Richard Barker – a key opinion leader on UK healthcare – gives his take on the recently launched ‘Life Sciences Industrial Strategy’, the importance of…
Warwick Smith, director general of the British Generic Manufacturers Association (BGMA), discusses the potential impact of Brexit and recent policy changes on the British generics industry and extols the benefits…
Simon Gillespie of the British Heart Foundation (BHF), the UK’s leading national heart charity, outlines the organization’s mission, the issues surrounding translational research, and the potential impact of Brexit on…
Hilary Evans of Alzheimer’s Research UK (ARUK), the UK’s leading national research charity in the field of dementia, discusses her organization’s mission; the growing awareness of, and investment in, dementia…
See our Cookie Privacy Policy Here
